Clinical trial data show that while fat mass accounts for the majority of weight loss, some lean mass reduction also occurs, which could potentially affect muscle function
Our team reviews your coverage, aligning you with providers who accept your plan and the medication that's covered for weight loss purposes
Target Consumer Segments Adults With Weight Management Goals (2550) : men and women seeking therapeutic supplementation to support appetite control, metabolic balance, and sustainable weight loss Adults With Pre-diabetes Or Type 2 Diabetes (3060) : individuals requiring preventative and therapeutic support for blood sugar regulation and improved insulin sensitivity Obese And Overweight Consumers (2555) : patients and health-conscious adults addressing obesity-related health risks who benefit from GLP-1 boosting supplementation Seniors (60+) : older adults managing metabolic slowdown, reduced satiety, and elevated cardiovascular risks who require preventative support for healthy aging Fitness Enthusiasts (2040) : active adults seeking appetite regulation, energy balance, and weight management supplementation to complement their fitness routines Patients In Recovery : individuals post-treatment or managing chronic metabolic conditions who need therapeutic nutritional support for stabilization and rehabilitation Regional Consumer Demand North America Market Insight : Rising awareness of weight management and metabolic health is driving demand for GLP-1 supplements, particularly in the wellness and fitness sectors
Eric Strong @DrEricStrong - Strong Medicine #GLP1 #Receptor #Agonists #Pharmacology #Summary #DM2 #diabetes #endocrinology
Pharmaceutical companies are sniffing out new territory, tapping the same science behind blockbuster weight-loss drugs like Ozempic and Wegovy to develop similar treatments for pets
